Eileen Rojas

With lagging sales, Abercrombie is re-branding Hollister to tap into the success achieved by its fast-fashion competitors.

Safeway may soon join forces with Albertsons, as private equity owner Cerberus Capital Management continues to buy up grocery stores.

The harsh winter weather had a negative impact on some retailers during February, while some managed to come out ahead.

Office supply retailer Staples will close several of its locations, as its e-commerce site reports higher growth.

Costco missed EPS estimates for the second quarter, but the company’s solid operating strategy should maintain long-term profitability.

Will J. Crew become the next hot retail stock?

Dialysis treatment provider Rockwell Medical’s sales have been rising, but is the stock a good purchase?

Like some of its competitors, Merck is looking to streamline its business and put greater focus on its core products.

After its anti-clotting agent Cangrelor was rejected by an FDA committee, The Medicines Company sets its sights on getting approval for skin infection drug oritavancin.

A new study showed the efficacy of using Lyrica to treat Restless Legs Syndrome over another treatment -- Boehringer Ingelheim’s Mirapex.

As Community Health Systems reports fiscal 2013 fourth quarter earnings later today, investors should look for updates on the following key areas.

AstraZeneca reported disappointing fourth quarter revenues but showed progress with an Alzheimer's therapy the company has under development.

Some key areas for investors to consider when acute care hospital operator LifePoint Hospitals releases its fourth quarter earnings on Friday.

Pfizer is working on an experimental drug for breast cancer and expanding use of a pneumonia vaccine to offset losses from patent expirations.

The latest trial for Medtronic’s renal denervation system, a procedure used to treat drug-resistant blood pressure, was negatively impacted by the placebo effect.

Merck’s new heart attack therapy, vorapaxar, gets favorable FDA review, as a recent study shows it reduces the risk of cardiovascular death.

Google scheduled a meet-and-greet with the FDA, raising speculation that an eye device with biosensors may be on the drawing board.

GlaxoSmithKline receives FDA approval on a novel treatment combination for late-stage melanoma.

As The Container Store deals with the costs of its recent IPO, cost containment will be key for future growth.

Bristol-Myers Squibb and AstraZeneca received FDA approval for their jointly developed diabetes drug Farxiga, but several post-market studies must be conducted.